SCHEMBL3380722

SCHEMBL3380722

CC(C)(C)[Si](C)(C)OCCNc1cccc(CN2Cc3cccc(NC(=O)c4ccc(Cl)s4)c3C2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.48
ACKR3 P25106 2/20 0.39
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 1/20 0.36
CREBBP Q92793 1/20 0.36
TP53 P04637 2/20 0.35
USP2 O75604 2/20 0.35
MAPT P10636 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALDH1A1 P00352 5/20 0.35
POLB P06746 2/20 0.35
ESR2 Q92731 1/20 0.35
MCL1 Q07820 1/20 0.34
MAPK1 P28482 1/20 0.34
NR1I2 O75469 1/20 0.34
UGCG Q16739 1/20 0.34
PARP1 P09874 1/20 0.34
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379883 0.94 F10 (0.47) F10MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3378168 0.89 F10 (0.63) F10ACKR3MEN1KMT2ASMN1; SMN2
SCHEMBL3379941 0.86 F10 (0.53) F10ACKR3MEN1KMT2ASMN1; SMN2
SCHEMBL3381123 0.84 F10 (0.43) F10ACKR3MEN1KMT2ASMN1; SMN2
SCHEMBL3381165 0.84 POLB (0.40) F10SMN1; SMN2TP53MAPTTDP1
SCHEMBL3379830 0.82 F10 (0.40) F10MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3382382 0.79 F10 (0.55) F10ACKR3MEN1KMT2ASMN1; SMN2
SCHEMBL3377544 0.78 F10 (0.51) F10MEN1KMT2ASMN1; SMN2TP53
SCHEMBL5782990 0.78 F10 (0.55) F10ACKR3MEN1KMT2ASMN1; SMN2
SCHEMBL3376468 0.76 AHR (0.40) F10SMN1; SMN2ALDH1A1MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029586-B1 ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF BAYER SCHERING PHARMA AG (DE) 2010-11-24 EP disclosed
US-20100010060-A1 Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2010-01-14 US disclosed
US-20100010060-A1 Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010060-A1 Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof ICAM1, SERPINC1, TFPI2 F10 264/4885ACKR3 3525/4885MEN1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.